ERBB2 and non-small cell lung carcinoma: The role of immunotherapy in HER2 altered NSCLC remains unclear and while there is unlikely to be a clinical trial of immunotherapy specifically in this patient population, a better understanding of the tumor immune microenvironment in HER2 altered NSCLC could allow for more rational use of these agents in this patient population.